



NABP
National Association of
Boards of Pharmacy

Educational, Regulatory, and Association News

NABP Membership Approves Six Resolutions at the Association's 117th Annual Meeting

Delegates from the member boards of pharmacy adopted six resolutions during the 117th NABP Annual Meeting, held virtually on May 13-14, 2021. The resolutions addressed pandemic-related issues, drug importation, and pharmacist workplace conditions, and more.

[Read the Full Press Release](#)

2021-2022 Executive Committee Inaugurated at NABP's 117th Annual Meeting

Delegates to the 117th NABP Annual Meeting, held virtually on May 13-14, 2021, elected individuals to fill the president-elect, treasurer, and open member positions on the Association's 2021-2022 Executive Committee.

The newly elected officers of the NABP Executive Committee are:

- President-elect Reginald B. "Reggie" Dilliard, DPh;
- Treasurer Lenora S. Newsome, PD;
- Member Deborah C. Mack, RPh, CHC, CCEP, three-year term (District 6); and
- Member Nicole L. Chopski, PharmD, BCGP, ANP, second three-year term (District 7).

The following NABP Executive Committee officers and members are continuing to fulfill their terms:

Like

Tweet

Share this Page: powered by 

the office after serving a one-year term as NABP president-elect;

- Chairperson Timothy D. Fensky, RPh, DPh, FACA, who assumed the position after serving one-year terms as president and president-elect;
- Member Bradley S. Hamilton, RPh (District 1);
- Member Tejal J. Patel, MBA, PharmD, RPh (District 2);
- Member Jeffrey J. Mesaros, PharmD, JD, RPh (District 3);
- Member Fred M. Weaver, RPh, (District 4);
- Member Shane R. Wendel, PharmD, RPh (District 5); and
- Member Kamlesh “Kam” Gandhi, PharmD, RPh (District 8).

[Read the Full Bios](#)

NABP Announces 2021 Leaders at the Forefront of Public Health Protection

NABP has announced its leaders in the protection of public health for 2021. Each year, the Association presents awards to individuals who have worked with unwavering dedication to ensure NABP’s continued service to the regulation of pharmacy practice and its efforts to assist the state boards of pharmacy in protecting the public health.

This year’s leaders include:

- Elizabeth Scott Russell, RPh, 2021 Carmen A. Catizone Honorary President Award recipient;
- Timothy D. Fensky, RPh, DPh, FACA, 2020-2021 NABP President’s Award recipient;
- Washington State Pharmacy Quality Assurance Commission, 2021 Fred T. Mahaffey Award recipient;
- Joanne M. Trifone, RPh, 2021 John F. Atkinson Service Award recipient;
- Parmjit K. Agarwal, PharmD, MBA, 2021 Henry Cade Memorial Award recipient, in recognition of the work of Pfizer Inc; and
- Philip P. Burgess, RPh, DPh, MBA, 2021 Lester E. Hosto Distinguished Service Award recipient.

[Read the Full Bios](#)

Like

Tweet

Share this Page: powered by 

Offered to Patients Outside the Scope of an Approved BLA

Food and Drug Administration (FDA) has issued a warning of biological products being offered to patients that appear to have been prepared by state-licensed pharmacies, registered outsourcing facilities, and health care providers outside the scope of an approved biologics license application (BLA). FDA reminds licensees that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved BLA. State boards of pharmacy are encouraged to submit to FDA any issues or questions involving the preparation of biological products outside the scope of an approved BLA.

[Learn More](#)

New USP Guide Provides Strategies, Techniques for Maximizing Moderna's COVID-19 Vaccine Doses

The United States Pharmacopeial Convention (USP) released a new guide, *Maximizing Doses of Moderna COVID-19 Vaccine*, to provide strategies and techniques to help safely maximize Moderna's doses. The guide goes over optimizing vial pressure and other useful techniques for preparation and maximizing doses from each vial. USP also has a similar guide called *Maximizing Doses of Pfizer-BioNTech COVID-19 Vaccine*, which is available for download.

[Learn More and Download the Guides](#)

New Study Shows Extended-Release Buprenorphine is Preferred by Patients in Treating OUD

Like

Tweet

Share this Page: 

powered by 

release injection versus the daily oral immediate-release buprenorphine, according to a new study highlighted by the National Institute on Drug Abuse. The researchers of the study found that the extended-release injection of buprenorphine was well-tolerated, acceptable to patients, and produced generally more positive patient-reported outcomes compared to daily oral buprenorphine. The [study](#) compared the outcomes for the daily buprenorphine treatment tablets that are given under the tongue, compared to a weekly or monthly injection of extended-release buprenorphine for OUD.

[Learn More About the Study](#)

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for EUA in Adolescents

FDA has expanded the emergency use authorization (EUA) for the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine to adolescents ages 12 through 15. The original EUA was issued for individuals 16 and older. FDA noted that this step is significant in stopping the spread of COVID-19.

[Read FDA's Full Press Release](#)



FOLLOW US

[View this email in your browser](#)

NABP e-News is a weekly publication prepared by NABP. Please send any comments, questions, or suggestions about the electronic newsletter to commdept@nabp.pharmacy. We look forward to receiving your feedback.



NABP
National Association of
Boards of Pharmacy

Educational, Regulatory, and Association News

Reminder: Share Feedback on ACPE Standards Revision Process

The Accreditation Council for Pharmacy Education (ACPE) seeks comments from all stakeholders via a survey related to its *Accreditation Standards and Key Elements for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree*. [Stakeholder feedback](#) will be used to develop the new “Standards 2025,” which will guide accreditation of the doctor of pharmacy programs into the 2030s. The target for the new standards release is July 2024 with full implementation planned for July 2025.

Share Your
Feedback

Counterfeit Pill Production Remains a Nationwide Threat, Updated Report Urges Action

Illegal pill presses remain prominent in the distribution of dangerous counterfeit drugs, including fentanyl, in the United States and the problem is not going away, according to a new report from The Partnership for Safe Medicines (PSM) and the National Association of Drug Diversion Investigators. The report, [Illegal Pill Presses: An Overlooked Threat to American Patients](#), indicates that pressed counterfeit pills made with fentanyl have been found in all 50 US states and are linked to deaths in 42 states. PSM urges federal action on the issue, noting that little legal or regulatory progress has been made in the last couple of years.

Watch the Video

Like

Tweet

Share this Page: powered by 

New CDC Study Shows COVID-19 Vaccines Are 94% Effective at Preventing Illness Among Health Care Workers

A new Centers for Disease Control and Prevention (CDC) study shows real-world evidence of the effectiveness of the mRNA vaccines to protect health care workers against coronavirus disease 2019 (COVID-19). CDC noted that the vaccines have reduced the risk of getting sick with COVID-19 by 94% among health care workers who have been fully vaccinated. The [findings](#) from this study were first reported in March 2021, and include a sampling from a network of over 500,000 health care workers across 33 sites in 25 US states.

[Read the Full CDC Press Release](#)

Study Results Show Pfizer's COVID-19 Vaccine Provides Strong Protection Against Variants

A study has shown that the Pfizer-BioNTech vaccine provides strong protection against variants of concern for COVID-19. Recent real-world data from Qatar showed that the Pfizer-BioNTech vaccine (two shots) is about 90% effective at preventing infections caused by variants, according to the study, which was published in [The New England Journal of Medicine](#). One of the key findings from the study is that even though Pfizer is a two-dose shot, after just one dose of the vaccine there was a significantly high level of protection. After one dose of the Pfizer vaccine, it provided 30% protection against the variant of concern.

[Learn More](#)

Warning Letter Issued for Unapproved and Misbranded COVID-19 Products

Food and Drug Administration (FDA) and the Federal Trade Commission have issued a warning letter to BGP, LLC, for unapproved and misbranded products related to COVID-19. FDA reviewed one of the products offered on the BGP website, which offers BIOCENCE WS Multi-use Selective Antibacterial / Antiviral

Like

Tweet

Share this Page: 

powered by 

COVID-19. FDA reminds consumers not to buy or use products that have not been approved, cleared, or authorized by FDA and that claim to treat COVID-19.

[Read the Warning Letter](#)



FOLLOW US

[View this email in your browser](#)

NABP e-News is a weekly publication prepared by NABP. Please send any comments, questions, or suggestions about the electronic newsletter to commdept@nabp.pharmacy. We look forward to receiving your feedback.